<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119011</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2018-204</org_study_id>
    <nct_id>NCT04119011</nct_id>
  </id_info>
  <brief_title>Probiotics in Women With Primary Dysmenorrhoea</brief_title>
  <official_title>A Novel Approach to Manipulate Intestinal Homeostasis in Primary Dysmenorrhoea Women: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B-Crobes Marketing(M) Sdn Bhd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of probiotics versus placebo in women with primary
      dysmenorrhoea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial comparing probiotics against placebo in women with
      primary dysmenorrhoea
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>placebo and probiotic are labelled A or B, this is prepared by the manufacturer and blinded from the participant and investigator, the unblinding takes place only after completion of the data collection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of inflammatory markers pre-treatment</measure>
    <time_frame>On the date of randomization</time_frame>
    <description>mean concentration of serum pro-inflammatory markers on day 2 of menses (Interleukin-1,2,4,5,6,7,8,10,12p70,13,17, Tumour necrosis factor-alpha, Granulocyte Colony Stimulating Factor, and Regulated on activation normal T-cell expressed and secreted) all in pg/mL, reported individually in table form</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of inflammatory markers post-treatment</measure>
    <time_frame>At 3 months after commencement of treatment</time_frame>
    <description>mean concentration of serum pro-inflammatory markers on day 2 of menses (Interleukin-1,2,4,5,6,7,8,10,12p70,13,17, Tumour necrosis factor-alpha, Granulocyte Colony Stimulating Factor, and Regulated on activation normal T-cell expressed and secreted) all in pg/mL, reported individually in table form</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score before and after treatment (visual analog score)</measure>
    <time_frame>on the date of randomization and at 3 month after completed treatment with probiotic or placebo</time_frame>
    <description>mean Visual Analog Score on scale 0 to 10, on day 2 of menses before and 3 month after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain score before and after treatment (verbal rating score)</measure>
    <time_frame>on the date of randomization and at 3 months after completed treatment with probiotic or placebo</time_frame>
    <description>mean Verbal Rating Score on scale 0 to 3, on day 2 of menses before and 3 month after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) use between placebo and probiotic group</measure>
    <time_frame>3 months during treatment with probiotic or placebo</time_frame>
    <description>mean number of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) use per cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life before and after treatment</measure>
    <time_frame>on date of randomization and at 3 months after completed treatment with probiotic or placebo</time_frame>
    <description>mean quality of life score using validated health survey questionnaire Short Form 12 version 2 (SF12v2) (permission obtained from primary author) Answers from each question will be calculated using formula into percentage of average physical health score and average mental health score, on scale 0 to 100 in which higher percentage represents higher quality of life, and score less than 50 represents poor quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intestinal microbiota before and after treatment with probiotics</measure>
    <time_frame>on date of randomization and at 3 month after completed treatment with probiotic or placebo</time_frame>
    <description>Relative abundance of microbiome DNA in percentage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Primary Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic in powder form containing lactobacillus and bifidobacterium strains, sugar, milk powder and flavoring, taken 2 sachets daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in powder form containing sugar, milk powder, flavoring, taken 2 sachets daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  regular menstrual cycles between 21 to 45 days

          -  primary dysmenorrhoea only

          -  willing to consume sachets twice daily for 3 months

        Exclusion Criteria:

          -  current Intrauterine Copper Device (IUCD) user

          -  recent hormonal (estrogen or progesterone) therapy in last 3 months

          -  on treatment for allergy such as antihistamine

          -  diarrhoea with dairy product

          -  often take drugs which may affect the test results (such as medicines treating
             constipation or digestive medicine such as laxatives or enema)

          -  any malignant tumor regardless of type or site
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nur Azurah Abd Ghani</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University of Malaysia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University of Malaysia</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Prof Dr Nur Azurah Abd Ghani</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>clinical data sheet containing demographics, data collection (pain score, quality of life questionnaire, pain diary)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>20 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

